

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Technology Appraisal no. 47; Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Eli Lilly (abciximab) • GlaxoSmithKline (eptifibatide) • Iroko (tirofiban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Arrhythmia Association • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • Cardiac Risk in the Young • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Heart Care Partnership (UK) • HEART UK • Muslim Council of Great Britain • Muslim Health Network • National Heart Forum • Network of Sikh Organisations • SADS UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists Collaboration • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts and The London • Cardiovascular Diseases Specialist Library • Cochrane Heart Group • Cochrane Peripheral Vascular Diseases Group

National Institute for Health and Clinical Excellence

Technology Appraisal no. 47; Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Issue date: April 2010

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association of Emergency Medicine • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Nuclear Cardiology Society • British Society of Cardiac Radiology • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society of Cardiothoracic Surgeons • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Barnet • NHS North Lancashire • Welsh Assembly Government 	<ul style="list-style-type: none"> • CORDA • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • Wellcome Trust <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • tbc <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • none

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

National Institute for Health and Clinical Excellence

Technology Appraisal no. 47; Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Issue date: April 2010

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute)

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Technology Appraisal no. 47; Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Issue date: April 2010